In this issue:
RRSO and breast cancer risk
Benchmarking patient care
Impact of dietary supplements on survival outcomes
Complementary and alternative medicine use
Adjuvant chemotherapy and recurrence dynamics
Tucatinib for HER2+ mBC
Trastuzumab deruxtecan in HER2+ mBC
Long-term OS with pertuzumab in HER2+ mBC
Pembrolizumab for TNBC
OS with ribociclib + fulvestrant
Please login below to download this issue (PDF)